Repository logo
 

The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease.

Simple item page
dc.contributor.authorQarin, Shamma
dc.contributor.authorHowlett, Sarah K
dc.contributor.authorJones, Joanne L
dc.contributor.authorBarker, Roger A
dc.contributor.orcidQarin, Shamma [0000-0002-9454-365X]
dc.date.accessioned2021-10-25T00:39:26Z
dc.date.available2021-10-25T00:39:26Z
dc.date.issued2021-09-13
dc.date.updated2021-10-25T00:39:26Z
dc.description.abstractDopaminergic (DA) cell replacement therapies are a promising experimental treatment for Parkinson's disease (PD) and a number of different types of DA cell-based therapies have already been trialled in patients. To date, the most successful have been allotransplants of foetal ventral midbrain but even then, the results have been inconsistent. This coupled to the ethical and logistical problems with using this tissue has meant that an alternative cell source has been sought of which human pluripotent stem cells (hPSCs) sources have proven very attractive. Robust protocols for making mesencephalic DA (mesDA) progenitor cells from hPSCs now exist and the first in-human clinical trials have or are about to start. However, while their safety and efficacy are well understood, relatively little is known about their immunogenicity and in this review, we briefly summarise this with reference mainly to the limited literature on human foetal DA cells.
dc.identifier.doi10.17863/CAM.77282
dc.identifier.issn2059-6553
dc.identifier.otherPMC8438115
dc.identifier.other34552761
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/329837
dc.languageeng
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceessn: 2059-6553
dc.sourcenlmid: 101721079
dc.subjectImmunogenicity
dc.subjectTransplant
dc.subjectImmune rejection
dc.subjectParkinson’s Disease
dc.subjectDopaminergic
dc.subjectHuman Foetal Ventral Midbrain
dc.titleThe immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease.
dc.typeArticle
prism.issueIdentifier3
prism.publicationNameNeuronal signaling
prism.volume5
pubs.funder-project-idWellcome Trust (203151/Z/16/Z)
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1042/ns20200083

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
article.pdf
Size:
634.73 KB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
https://creativecommons.org/licenses/by/4.0/
Download

Collections

Jisc Publications Router